135 related articles for article (PubMed ID: 29768022)
1. A pharmaceutical industry perspective on transporter and CYP-mediated drug-drug interactions: kidney transporter biomarkers.
Shen H
Bioanalysis; 2018 May; 10(9):625-631. PubMed ID: 29768022
[No Abstract] [Full Text] [Related]
2. Application of in vitro CYP and transporter assays to predict clinical drug-drug interactions.
Volpe DA; Balimane PV
Bioanalysis; 2018 May; 10(9):619-623. PubMed ID: 29768028
[No Abstract] [Full Text] [Related]
3. Transporter-mediated drug interactions: clinical implications and in vitro assessment.
Lin JH
Expert Opin Drug Metab Toxicol; 2007 Feb; 3(1):81-92. PubMed ID: 17269896
[TBL] [Abstract][Full Text] [Related]
4. Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions.
Chu X; Chan GH; Evers R
J Pharm Sci; 2017 Sep; 106(9):2357-2367. PubMed ID: 28416420
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
6. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats.
Naud J; Michaud J; Beauchemin S; Hébert MJ; Roger M; Lefrancois S; Leblond FA; Pichette V
Drug Metab Dispos; 2011 Aug; 39(8):1363-9. PubMed ID: 21525170
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for In Vivo Assessment of Transporter Function.
Müller F; Sharma A; König J; Fromm MF
Pharmacol Rev; 2018 Apr; 70(2):246-277. PubMed ID: 29487084
[TBL] [Abstract][Full Text] [Related]
8. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.
Soars MG; Webborn PJ; Riley RJ
Mol Pharm; 2009; 6(6):1662-77. PubMed ID: 19402709
[TBL] [Abstract][Full Text] [Related]
9. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
Kasserra C; Assaf M; Hoffmann M; Li Y; Liu L; Wang X; Kumar G; Palmisano M
J Clin Pharmacol; 2015 Feb; 55(2):168-78. PubMed ID: 25159194
[TBL] [Abstract][Full Text] [Related]
10. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells.
Ulvestad M; Nordell P; Asplund A; Rehnström M; Jacobsson S; Holmgren G; Davidson L; Brolén G; Edsbagge J; Björquist P; Küppers-Munther B; Andersson TB
Biochem Pharmacol; 2013 Sep; 86(5):691-702. PubMed ID: 23856292
[TBL] [Abstract][Full Text] [Related]
11. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
12. [Transporter-mediated drug-drug interaction in renal and hepatic elimination processes].
Nagai J
Nihon Yakurigaku Zasshi; 2010 Jan; 135(1):34-7. PubMed ID: 20075569
[No Abstract] [Full Text] [Related]
13. Evaluation of New Chemical Entities as Substrates of Liver Transporters in the Pharmaceutical Industry: Response to Regulatory Requirements and Future Steps.
Okudaira N
J Pharm Sci; 2017 Sep; 106(9):2251-2256. PubMed ID: 28533120
[TBL] [Abstract][Full Text] [Related]
14. Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant?
Lepist EI; Ray AS
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S73-81. PubMed ID: 27385181
[TBL] [Abstract][Full Text] [Related]
15. The kidney--the body's playground for drugs: an overview of renal drug handling with selected clinical correlates.
Perri D; Ito S; Rowsell V; Shear NH
Can J Clin Pharmacol; 2003; 10(1):17-23. PubMed ID: 12687033
[TBL] [Abstract][Full Text] [Related]
16. Transporters as a determinant of drug clearance and tissue distribution.
Shitara Y; Horie T; Sugiyama Y
Eur J Pharm Sci; 2006 Apr; 27(5):425-46. PubMed ID: 16488580
[TBL] [Abstract][Full Text] [Related]
17. Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.
Mogalian E; German P; Kearney BP; Yang CY; Brainard D; McNally J; Moorehead L; Mathias A
Clin Pharmacokinet; 2016 May; 55(5):605-13. PubMed ID: 26519191
[TBL] [Abstract][Full Text] [Related]
18. Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide).
Subramanian R; Zhu X; Kerr SJ; Esmay JD; Louie SW; Edson KZ; Walter S; Fitzsimmons M; Wagner M; Soto M; Pham R; Wilson SF; Skiles GL
Drug Metab Dispos; 2016 Aug; 44(8):1319-31. PubMed ID: 26895981
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.
Zhang H; Cui D; Wang B; Han YH; Balimane P; Yang Z; Sinz M; Rodrigues AD
Clin Pharmacokinet; 2007; 46(2):133-57. PubMed ID: 17253885
[TBL] [Abstract][Full Text] [Related]
20. [Progress in regulation of drug transporters and metabolic enzymes by resveratrol].
Jia YM; Liu ZH; Liu KX
Yao Xue Xue Bao; 2016 Jun; 51(6):860-5. PubMed ID: 29878738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
